Expression of RFC/SLC19A1 is associated with tumor type in Bladder cancer patients

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Abdel Haleem, Alyaa M ^a   El Zeiry, Maha I ^a   Mahran, Laila G ^a   Abou Aisha, Khaled ^a   Rady, Mona H ^a   Rohde, Jan ^a,c   Mostageer, Marwa ^a,d   Spahn Langguth, Hilde ^a,b  

^a German University in Cairo   (Egypt)

^b UNIVERSITY OF GRAZ   (Austria)

^c Minapharm Pharmaceuticals   (Egypt)

^d AFFiRiS GmbH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FOLIC ACID ANTAGONIST; MESSENGER RNA; REDUCED FOLATE CARRIER; SLC19A1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; PREDICTION; PROGNOSIS; QUANTITATIVE ANALYSIS; REDUCED FOLATE CARRIER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEADY STATE; TRANSITIONAL CELL CARCINOMA; TUMOR DIFFERENTIATION; BIOLOGICAL MODEL; BIOPSY; BLADDER TUMOR; CLASSIFICATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; STANDARD;

MAMMALIA;

ADULT; AGED; BIOPSY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; REDUCED FOLATE CARRIER PROTEIN; REFERENCE STANDARDS; RNA, MESSENGER; URINARY BLADDER NEOPLASMS;

EID: 79960126955     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021820     Document Type: Article

References (35)

1. Matherly LH, Hou Z, Deng Y, (2007) Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Rev 26: 111-128.
2. Schabath MB, Spitz MR, Lerner SP, Pillow PC, Hernandez LM, et al. (2005) Case-control analysis of dietary folate and risk of bladder cancer. Nutr Cancer 53: 144-151.
3. Parkin DM, (2008) The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl pp. 12-20.
4. Greene FL, Compton CC, Frtiz AG, Shah JP, Winchester DP, eds. (2006) AJCC Cancer Staging Atlas:Springer Science+Business Media, Inc.
5. Felix AS, Soliman AS, Khaled H, Zaghloul MS, Banerjee M, et al. (2008) The changing patterns of bladder cancer in Egypt over the past 26 years. Cancer Causes Control 19: 421-429.
6. Ploeg M, Aben KK, Kiemeney LA, (2009) The present and future burden of urinary bladder cancer in the world. World J Urol 27: 289-293.
7. Memon AA, Sorensen BS, Melgard P, Fokdal L, Thykjaer T, et al. (2004) Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients. Br J Cancer 91: 2034-2041.
8. Reznikoff CA, Sarkar S, Julicher KP, Burger MS, Puthenveettil JA, et al. (2000) Genetic alterations and biological pathways in human bladder cancer pathogenesis. Urol Oncol 5: 191-203.
9. Ueki O, Hisazumi H, Uchibayashi T, Naito K, Tajiri S, et al. (1992) Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced urothelial cancer. Cancer Chemother Pharmacol 30 (Suppl): S72-76.
10. Matherly LH, Goldman DI, (2003) Membrane transport of folates. Vitam Horm 66: 403-456.
11. Matherly LH, Hou Z, (2008) Structure and Function of the Reduced Folate Carrier: A Paradigm of a Major Facilitator Superfamily Mammalian Nutrient Transporter Vitamins and Hormones El Sevier Inc.
12. Matherly LH, Hou Z, (2008) Structure and function of the reduced folate carrier a paradigm of a major facilitator superfamily mammalian nutrient transporter. Vitam Horm 79: 145-184.
13. Goldman ID, Matherly LH, (1985) The cellular pharmacology of methotrexate. Pharmacol Ther 28: 77-102.
14. Goldman ID, Zhao R, (2002) Molecular, biochemical, and cellular pharmacology of pemetrexed. Semin Oncol 29: 3-17.
15. Assaraf YG, (2007) Molecular basis of antifolate resistance. Cancer Metastasis Rev 26: 153-181.
16. Bradely D, Hussain M, (2010) Beyond MVAC: New and Improved Chemotherapeutics. pp. 247-262 Bladder Cancer: Diagnosis, Therapeutics, and Management: Humana Press. Part 3.
17. Guo W, Healey JH, Meyers PA, Ladanyi M, Huvos AG, et al. (1999) Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res 5: 621-627.
18. Whetstine JR, Matherly LH, (2001) The basal promoters for the human reduced folate carrier gene are regulated by a GC-box and a cAMP-response element/AP-1-like element. Basis for tissue-specific gene expression. J Biol Chem 276: 6350-6358.
19. Erdemir F, Tunc M, Ozcan F, Parlaktas BS, Uluocak N, et al. (2007) The effect of squamous and/or glandular differentiation on recurrence, progression and survival in urothelial carcinoma of bladder. Int Urol Nephrol 39: 803-807.
20. Sowers R, Toguchida J, Qin J, Meyers PA, Healey JH, et al. (2003) mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma. Mol Cancer Ther 2: 535-541.
21. Gorlick R, (2000) Methorexate, its mechanism of action in malignant disease and mechanisms of resistance by malignant cells. In: Bertino JR, Cronstein BN, editors. Milestones in Drug Therapy: Methotrexate Berlin Birkhauser pp. 9-29.
22. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, et al. (2009) The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55: 611-622.
23. Ohl F, Jung M, Radonic A, (2005) Identification and validation of suitable endogenous reference genes for gene espression studies of human bladder cancer. The Journal of Urology 175: 1915-1920.
24. Schmittgen TD, Livak KJ, (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101-1108.
25. Sirotnak FM, Tolner B, (1999) Carrier-mediated membrane transport of folates in mammalian cells. Annu Rev Nutr 19: 91-122.
26. Flatley RM, Payton SG, Taub JW, Matherly LH, (2004) Primary acute lymphoblastic leukemia cells use a novel promoter and 5′noncoding exon for the human reduced folate carrier that encodes a modified carrier translated from an upstream translational start. Clin Cancer Res 10: 5111-5122.
27. Zhang L, Taub JW, Williamson M, Wong SC, Hukku B, et al. (1998) Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia: relationship to immunophenotype and ploidy. Clin Cancer Res 4: 2169-2177.
28. Frisch M, Klocke B, Haltmeier M, Frech K, (2009) LitInspector: literature and signal transduction pathway mining in PubMed abstracts. Nucleic Acids Res 37: W135-140.
29. Wu XR, (2005) Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 5: 713-725.
30. Haitel A, Posch B, El-Baz M, Mokhtar AA, Susani M, et al. (2001) Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2. J Urol 165: 1481-1487.
31. Eissa S, Ali-Labib R, Khalifa A, (2000) Deletion of p16 and p15 genes In schistosomiasis-associated bladder cancer (SABC). Clin Chim Acta 300: 159-169.
32. Rothem L, Aronheim A, Assaraf YG, (2003) Alterations in the expression of transcription factors and the reduced folate carrier as a novel mechanism of antifolate resistance in human leukemia cells. J Biol Chem 278: 8935-8941.
33. Rothem L, Stark M, Assaraf YG, (2004) Impaired CREB-1 phosphorylation in antifolate-resistant cell lines with down-regulation of the reduced folate carrier gene. Mol Pharmacol 66: 1536-1543.
34. Choi SW, Mason JB, (2000) Folate and carcinogenesis: an integrated scheme. J Nutr 130: 129-132.
35. Blount BC, Mack MM, Wehr CM, MacGregor JT, Hiatt RA, et al. (1997) Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. Proc Natl Acad Sci U S A 94: 3290-3295.